Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Hospital das Clínicas de Ribeirão Preto clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Brazil register with Hospital das Clínicas de Ribeirão Preto as lead sponsor. Synced 14 Nov 2026
6Current trials
2Recruiting now
7Drugs in these trials
1Trial register
At a glance

Hospital das Clínicas de Ribeirão Preto is the lead sponsor of 6 current clinical trials in our Brazil register. 2 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Nivolumab, Ipilimumab and Losartan. The most-studied condition is Obesity & Overweight.

ClinicalTrials.gov trials by status

  • Recruiting233%
  • Not yet open233%
  • Active, closed117%
  • By invitation117%

Trials by phase

  • Not applicable350%
  • Phase 2233%
  • Phase 1/2117%
01

Clinical trials sponsored by Hospital das Clínicas de Ribeirão Preto

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
NCT07084610 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Drug: Nivolumab
Phase 2 Recruiting 2025-02 Brazil
Obstructive Sleep Apnea Treatment From Acute to Chronic Phase of Stroke
NCT07044830 · ClinicalTrials.gov ↗ · Ischemic Stroke, Obstructive Sleep Apnea
Not applicable Recruiting 2024-02 Brazil
Rosuvastatin and Losartan Pharmacokinetics After Bariatric Surgery
NCT07748273 · ClinicalTrials.gov ↗ · Obesity & Overweight, Bariatric Surgery, Pharmacokinetics After Oral Intake
Not applicable Not yet open 2026-08 Brazil
Transit Bipartition After Sleeve Gastrectomy
NCT07728682 · ClinicalTrials.gov ↗ · Obesity & Overweight, Gastroesophageal Reflux (GERD), Weight Recurrence
Not applicable Not yet open 2026-08 Brazil
Melphalan Chemoreduction for Ocular Melanoma
NCT05893654 · ClinicalTrials.gov ↗ · Uveal Melanoma
Drug: Melphalan
Phase 1/2 By invitation 2021-05 Brazil
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
NCT05215470 · ClinicalTrials.gov ↗ · Renal Cancer Metastatic
Phase 2 Active, closed 2022-01 Brazil

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Hospital das Clínicas de Ribeirão Preto trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Hospital das Clínicas de Ribeirão Preto trials

11 conditions
Obesity & Overweight2Bariatric Surgery2Non-Small Cell Lung Cancer1Uveal Melanoma1Pharmacokinetics After Oral Intake1Drug Absorption1Ischemic Stroke1Obstructive Sleep Apnea1Renal Cancer Metastatic1Gastroesophageal Reflux (GERD)1Weight Recurrence1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in Brazil62

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Obesity & Overweight

SponsorTrials
Medipol University4
University College Dublin3
Wageningen University2
University Hospital, Gentofte, Copenhagen2
Poznan University of Life Sciences2
Universidade Cesumar (UNICESUMAR)2
Corxel Pharmaceuticals1
Bioagile Therapeutics1
Shanxi Bethune Hospital1
Universite du Littoral Cote d'Opale1

Sponsors with the most current trials registered for this condition.

06

Questions about Hospital das Clínicas de Ribeirão Preto trials

How many clinical trials does Hospital das Clínicas de Ribeirão Preto sponsor?

Hospital das Clínicas de Ribeirão Preto is the lead sponsor of 6 current trials on ClinicalTrials.gov in our Brazil register, as of the registry sync on 14 November 2026. Completed and withdrawn studies are not counted.

Are Hospital das Clínicas de Ribeirão Preto trials recruiting?

Yes. 2 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Hospital das Clínicas de Ribeirão Preto testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are Nivolumab (2), Ipilimumab (1), Losartan (1), Melphalan (1) and Opdivo (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 14 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.